Press release content from Globe Newswire. The AP news staff was not involved in its creation.
InspireMD Announces 1-for-15 Reverse Stock Split
InspireMD Inc.April 14, 2021 GMT
TEL AVIV, Israel, April 14, 2021 (GLOBE NEWSWIRE) InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced a 1-for-15 reverse split of its common stock, effective as of April 26, 2021. Beginning on April 27, 2021, the Company’s common stock will trade on the NYSE American on a split adjusted basis.
At InspireMD’s special meeting of stockholders on April 14, 2021, the Company’s stockholders authorized the Board of Directors to amend the Amended and Restated Certificate of Incorporation of the Company to effect a reverse stock split at a ratio in the range of 1-for-10 to 1-for-20.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
InspireMD Announces Fourth Quarter and Year-End 2020 Financial Results
InspireMD Inc.March 9, 2021 GMT
TEL AVIV, Israel, March 09, 2021 (GLOBE NEWSWIRE) InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the fourth quarter and year ended December 31, 2020.
Fourth Quarter 2020 and recent highlights:
Announced the closing of an upsized underwritten public offering of $20.7 million.
Announced the addition of renowned interventional cardiologist Gary Roubin, M.D., Ph.D., to the Board of Directors.
CGuard Carotid Embolic Protection Device Trial Will be Led by Chris Metzger
InspireMD s MicroNet embolic protection mesh on stents is designed to prevent emboli during carotid stenting.
February 9, 2021 InspireMD Inc., developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced the appointment of Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee as the principal investigator for its planned U.S. FDA registration trial for CGuard EPS.
This upcoming trial will investigate the safety and efficacy of InspireMD s MicroNet embolic protection system technology for carotid stenting. It is designed to prevent stroke during stent placement and help improve long-term outcomes.
Share:
TEL AVIV, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) InspireMD, Inc. (NYSE:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announced a transaction intended to achieve distribution of CGuard EPS in mainland China.
InspireMD s agreement with three China-based investment partners, including Shanghai Micro Medical (SMM) and QIDI Asia Medical, stipulates that the Chinese partners will be responsible for conducting all necessary registration trials for commercial approval, followed by an eight-year exclusive distribution right in China. In addition, QIDI has agreed to make a $900,000 investment in InspireMD s common stock at the closing price on the day immediately prior to entering into the transaction in a private placement. The transactions are expected to close this month. Following announcement of the transaction the Chinese partners plan to initiate the process of securing registration